In a trial, Pfizer-BioNTech’s low-dose shot did not provoke an adequate immune response in 2- to 5-year-olds.

Calling the vaccine a “three-dose series,” the company now plans to test three doses of its vaccine in children ages six months to 17 years.

from NYT > Top Stories